PF-07915048 Influenza saRNA — Competitive Intelligence Brief

PF-07915048 Influenza saRNA (pf-07915048-influenza-sarna) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RNA-based therapy. Area: Infectious Disease.

marketed RNA-based therapy influenza virus Infectious Disease

Target snapshot

PF-07915048 Influenza saRNA (pf-07915048-influenza-sarna) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PF-07915048 Influenza saRNA TARGET	pf-07915048-influenza-sarna	Pfizer	marketed	RNA-based therapy	influenza virus
Quadrivalent Influenza Vaccine	Quadrivalent Influenza Vaccine	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Inactivated vaccine	Influenza viruses
Quadrivalent influenza modRNA vaccine	quadrivalent-influenza-modrna-vaccine	Pfizer	marketed	Vaccine	Influenza virus
Qiv	qiv	Pfizer	marketed	Inactivated vaccine	Influenza viruses
PF-07871987 Influenza saRNA	pf-07871987-influenza-sarna	Pfizer	marketed	RNA-based therapeutic	influenza virus
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Fluad alone	Fluad alone	Korea University Guro Hospital	marketed	Inactivated influenza vaccine with adjuvant	Influenza virus hemagglutinin and neuraminidase antigens; MF59 acts as immunological adjuvant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RNA-based therapy class)

1. Pfizer · 2 drugs in this class